These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34117958)

  • 1. The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
    Al-Kawaz A; Miligy IM; Toss MS; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
    Breast Cancer Res Treat; 2021 Jul; 188(1):53-63. PubMed ID: 34117958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
    Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
    Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
    Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
    Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
    J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
    Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
    Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
    Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; McCaffrey L; AlKawaz A; Abidi A; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 May; 32(5):639-649. PubMed ID: 30429518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
    Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Khout H; Ellis IO; Green AR; Rakha EA
    Br J Cancer; 2018 Dec; 119(12):1518-1526. PubMed ID: 30410060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
    Woo JW; Choi HY; Kim M; Chung YR; Park SY
    Breast Cancer; 2022 Sep; 29(5):814-824. PubMed ID: 35451796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.
    Cedolini C; Bertozzi S; Londero AP; Seriau L; Andretta M; Agakiza D; Fongione S; Uzzau A; Risaliti A
    Int J Clin Exp Pathol; 2015; 8(10):13304-13. PubMed ID: 26722534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
    Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
    Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; Aleskandarany MA; Alkawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1460-1472. PubMed ID: 31175327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
    Moriya T; Silverberg SG
    Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.